{"a":[{"_":"J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout","$":{"href":"/biotech/jj-pays-sail-785m-charting-course-possible-vivo-car-t-buyout","hreflang":"en"}}]}

Positive

AI Analysis

Summary

Johnson & Johnson pays $785 million upfront to Sail Biomedicines, securing an option to potentially acquire the company and advance its in vivo CAR-T therapeutic program.

Outcome Details

J&J pays $785M upfront to Sail Biomedicines with option to acquire

Importance:7/10

Sentiment:

0.60

M&Ain vivo CAR-Timmunotherapycell therapy

Related Companies

$JNJ

Read the original article

Published by FierceBiotech on July 30, 2026 3:19 AM

Read Original